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A B S T R A C T
Sphingosine-1-phosphate (S1P) is a signaling lipid, synthetized by sphingosine kinases (SPHK1 and SPHK2), that
affects cardiovascular function in various ways. S1P signaling is complex, particularly since its molecular action
is reliant on the differential expression of its receptors (S1PR1, S1PR2, S1PR3, S1PR4, S1PR5) within various
tissues. Significance of this sphingolipid is manifested early in vertebrate development as certain defects in S1P
signaling result in embryonic lethality due to defective vasculo- or cardiogenesis. Similar in the mature or-
ganism, S1P orchestrates both physiological and pathological processes occurring in the heart and vasculature of
higher eukaryotes. S1P regulates cell fate, vascular tone, endothelial function and integrity as well as lym-
phocyte trafficking, thus disbalance in its production and signaling has been linked with development of such
pathologies as arterial hypertension, atherosclerosis, endothelial dysfunction and aberrant angiogenesis. Number
of signaling mechanisms are critical – from endothelial nitric oxide synthase through STAT3, MAPK and Akt
pathways to HDL particles involved in redox and inflammatory balance. Moreover, S1P controls both acute
cardiac responses (cardiac inotropy and chronotropy), as well as chronic processes (such as apoptosis and hy-
pertrophy), hence numerous studies demonstrate significance of S1P in the pathogenesis of hypertrophic/fibrotic
heart disease, myocardial infarction and heart failure. This review presents current knowledge concerning the
role of S1P in the cardiovascular system, as well as potential therapeutic approaches to target S1P signaling in
cardiovascular diseases.
1. Introduction
1.1. Sphingosine-1-phosphate- biosynthesis, localization and general
function
Although limited biological relevance has been attributed to lyso-
phospholipids for many years, the finding that sphingosine-1-phosphate
(S1P) has the ability to act as a ligand for G protein-coupled receptors
(GPCRs) has opened up novel research areas in lipid biology [1]. Cur-
rently, it is widely acknowledged that S1P possesses pleiotropic func-
tions and orchestrates many cellular processes including cell growth,
proliferation, migration and apoptosis [2–5]. S1P derives from phos-
pholipids building up cell membrane bilayer. Sphingomyelin is en-
zymatically metabolized by sphingomyelinase to produce ceramide
which is cleaved by ceramidase to form sphingosine [6]. Sphingosine-1-
phosphate is produced by the phosphorylation of sphingosine by
sphingosine kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2). The
level of S1P is further controlled through its irreversible degradation to
hexadecenal and ethanolamine phosphate by S1P lyase (SPL), as well as
through reversible dephosphorylation by sphingosine-1-phosphate
phosphatases (SPPs) or broad-specificity lipid phosphate phosphatases
(LPPs), and the latter are the only enzymes that are able to degrade
extracellular S1P [6,7].
S1P predominantly exists in the blood as it is mainly produced by
erythrocytes, endothelial cells (ECs) and, less efficiently, by activated
platelets [8,9]. Erythrocyte- and platelet-borne S1P is transported ex-
tracellularly via the major facilitator superfamily transporter 2b
(Mfsd2b), while ECs export S1P via the sphingolipid transporter 2
(Spns2) [10,11]. Studies reveal that both SPHKs are responsible for the
generation of the plasma S1P fraction. It has been demonstrated that
pharmacological and genetic inhibition of Sphk1 reduces plasma S1P
level by approximately half [12,13]. Surprisingly, Sphk2 knockout mice
have significantly higher S1P levels in plasma and in blood cells as
compared to wild-type animals [14,15]. This might be attributed to the
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fact that murine Sphk2 plays a role in the redistribution of erythrocyte-
borne S1P to ECs. More specifically, S1P produced by erythrocytes is
dephosphorylated by Lpp1 to produce sphingosine, which is then taken
up by ECs and re-phosporylated by Sphk2 to form intracellular S1P.
Thus, the lack of Sphk2 in mice results in S1P congestion in the blood
[14].
The concentration of S1P in the plasma ranges between 0.1 and 1.2
μM [10] (it is approximately 1/4 lower in the lymph as compared to
levels in the plasma) [16], while a smaller concentration of S1P has
been observed in tissues (0.5–75 pmol/mg) [17]. In general, there exists
a large S1P gradient between the blood/lymphatic circulatory system
and interstitial fluids [16]. To enhance the aqueous solubility of the
lipid in the blood and lymph, S1P is carried by various chaperone
proteins [18]. More than 50% of S1P is transported by high density
lipoproteins (HDLs). The remaining amount is bound to albumin
(30–40%), and less than 10% is transported by low density lipoproteins
(LDLs) and very low density lipoproteins (VLDLs) [7]. Importantly,
Murata and colleagues showed that HDL contains a much higher S1P
concentration than LDL [19], while Christoffersen et al. found that
apolipoprotein M is responsible for the binding of S1P to HDL [20].
Interaction of S1P with plasma proteins seems to lower its bioavail-
ability [21]. The type of S1P carrier affects its activity and metabolism
[7]. It has been observed that the half-life of HDL-bound S1P is 4-fold
higher than that of albumin-bound and such effect is due to prevention
of S1P degradation by ecto-phosphatases [22]. Moreover, the type of
carrier also has an impact on S1P receptor (S1PR) signaling [23]. Due to
the fact that HDL and S1P share common functional features, S1P is
believed to be one of the main determinants of HDL action [24,25].
1.2. Sphingosine kinases- structure, localization and function
Two isoenzymes responsible for S1P biosynthesis, SPHK1 and
SPHK2, originate from two separate genes located on chromosomes 17
and 19, respectively [26]. SPHKs consist of a C-terminal region and an
N-terminal region containing an ATP-binding site and a sphingosine
recognition site. Human SPHKs share 80% similarity with each other
and almost the entire SPHK2 polypeptide sequence aligns with the se-
quence of SPHK1. However, the SPHK2 isoform is considerably larger
due to the presence of two additional regions i.e. first one at the N-
terminal end and the other, proline-rich region, within the central part.
Additionally, several splicing variants of SPHK1 and SPHK2 which
differ in length and in amino acid composition of the N-termini have
been identified [26,27].
SPHK function is regulated in a spatial and temporal manner pri-
marily through phosphorylation, but also by the interaction with other
molecules [28,29]. However, during basal activity of SPHKs, ubiquitous
in cells, no post-translational modifications are required [29,30]. Under
physiological conditions SPHKs serve a housekeeping function in the
regulation of cell fate. They control a balanced level of pro-apoptotic
ceramide and sphingosine, and anti-apoptotic S1P, a phenomenon
known as “the sphingolipid rheostat” [31]. Upon stimulation with
various cytokines and growth factors, post-translational modifications
enhance SPHKs activity. Stimulation leads to increased S1P production
and its subsequent action as an intracellular signaling molecule or its
release outside of the cell and activation of signaling pathways medi-
ated by S1PRs.
Distinct subcellular localization of SPHK1 and SPHK2 is the main
determinant of their divergent function [32]. In unstimulated cells,
SPHK1 and SPHK2 are present mainly in a cytosolic form. However,
upon stimulation the SPHK1 isoform translocates to the plasma mem-
brane. This process is regulated via phosphorylation at Serine 225
(S225) by extracellular signal-regulated kinases 1/2 (ERK1/2), which
enhances activity of the enzyme [33]. Another important mechanism
that enables SPHK1 membrane relocalization is its calcium-mediated
association with calcium- and integrin-binding protein 1 (CIB1) [34]. In
general, SPHK1 activity promotes cell proliferation and survival [35].
The polypeptide sequence of SPHK2 contains a nuclear localization
signal (NSL) and a nuclear export signal (NES), which determines its
nuclear localization. In the nucleus SPHK2 can inhibit DNA synthesis
causing cell cycle arrest [36], and can inhibit histone deacetylases al-
tering epigenetic regulation of gene expression [37]. Moreover, it is
well established that under stress conditions, SPHK2 is also present in
endoplasmatic reticulum (ER), where it stimulates ceramide production
aiding the induction of apoptotic cell death [38]. Interestingly, SPHK2
is not present extracellularly, while approximately 8% of the inter-
cellular SPHK1 pool, is secreted outside the cell [39].
1.3. Sphingosine-1-phosphate receptors
Besides the S1P gradient in the body, the spatial distribution of S1P
receptors is a major determinant of S1P’s versatile role in the cardio-
vascular system [40]. Among five known GPCRs with a high affinity to
S1P, types 1, 2 and 3 are predominantly expressed in cardiovascular
tissues, while S1PR4 is characteristic of the lymphatic system and
S1PR5 is characteristic of the immune and nervous systems [41]. S1PRs
are coupled to specific G protein α subunits, which provides divergent
signaling responses. S1PR1 binds exclusively Gαi, which upon receptor
activation is released and reduces cyclic adenosine 3′,5′-monopho-
sphate (cAMP) level by cyclic adenylase inhibiton [42,43]. Gαi acti-
vation leads also to the upregulation of protein kinase C (PKC) isoform
α and ε and ERK1/2 signaling [44–46]. In addition to Gαi coupling,
S1PR2 and S1PR3 also couple with Gαq and Gα12/13, which activate
phospholipase C (PLC) and RhoA exchange factor signaling respectively
[40,41,46].
Cardiomyocytes, cardiac fibroblasts, endothelial cells and vascular
smooth muscle cells (VSMCs) demonstrate different patterns of S1PR
expression [47]. Although, these cells are characterized by the presence
of all three S1PRs, the difference in their expression level determines
unique downstream molecular consequences. S1P signaling in cardio-
myocytes is predominantly mediated by an abundant presence of
S1PR1 [48], while cardiac fibroblast express mainly S1PR3 [49].
VSMCs are characterized by a high S1PR2 and S1PR3 expression, with
much lower level of S1PR1 [46]. In contrast, S1PR1 is the main type of
receptor expressed by ECs, followed by S1PR3 and at a lessor frequency,
S1PR2 [50]. Specific S1P receptor affinity, as well as additional re-
ceptor-independent intracellular S1P actions, make the SPHK-S1P axis a
complex, yet important signaling pathway in the different cardiovas-
cular compartments.
2. S1P and embryonic development
The circulatory system is the first to develop during embryogenesis
in vertebrates and is essential for body function. Importantly, the
maintenance of a S1P balance is indispensable for a proper cardiovas-
cular development, and emphasizes the importance of S1P as a sig-
naling molecule (Fig. 1).
A net of newly formed vessels is created by aggregation of en-
dothelial progenitor cells in a process called vasculogenesis. Further
expansion of this primitive vascular plexus, involves remodeling, sta-
bilization and maturation to make a complex, fully functional network
of vessels [51]. In 2000, Liu and colleagues demonstrated that S1pr1-
null mice die in utero (between E12.5 and E14.5 day) as a result of
severe bleeding related to immaturity of the vasculature [52]. Further
studies provided evidence that other S1prs also contribute to vascu-
lature development. Kono et al. showed that triple S1pr1/S1pr2/S1pr3
knockout mice exhibit an even more severe phenotype as they die
earlier than S1pr1-null mice (between E10.5 and E11.5) [53]. More-
over, Mizugishi et al. revealed that Sphk1/Sphk2-null mice embryos die
prematurely before E13.5 due to inefficient vascularization, as well as
due to disturbed neurogenesis [54]. Furthermore, a study by Xiong
et al. established that red blood cells (RBCs) are the main source of
embryonic S1P necessary for normal vasculogenesis [55].
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The significance of S1P signaling in the heart is also evident as early
as the embryonic stage. Cardiomyocyte-specific knockout of S1pr1 is
perinatally lethal due to ventricular noncompaction with septation
defects [56]. Furthermore, cardiac endothelium-specific loss of S1pr1 is
linked to abnormal atrial and ventricular cardiomyocyte development,
as well as defects in coronary vasculature formation [57].
3. S1P and postnatal vascular homeostasis
While S1P signaling is essential for vascular development during the
embryonic stage, the maintenance of the postnatal S1P balance pro-
vides homeostasis for mature blood vessels. Studies have established a
multilayered action of S1P in postnatal vascular physiology and pa-
thology (Fig. 2). Investigators have revealed that S1P controls vascular
tone, endothelial barrier maintenance and directs lymphocyte traf-
ficking. Therefore the following section focuses on the consequences of
S1P dysregulation and signaling during hypertension (HT), athero-
sclerosis and angiogenesis [24,58,59].
3.1. S1P, vascular tone, lymphocyte trafficking and hypertension
HT is a disease of a multifactorial etiology and has a complex pa-
thophysiology [60]. A chronic increase in blood pressure (BP) has
substantial consequences for cardiovascular health and carries a high
risk for multi-organ pathology [61]. Vascular resistance and peripheral
endothelial dysfunction are classical hallmarks of this disorder. How-
ever, besides a well characterized involvement of the kidney and its
alteration of the renin-angiotensin-aldosterone system (RAAS), and ef-
fects generated from the sympathetic nervous system (SNS), which
becomes hyperactivated in HT, a growing body of evidence indicates
that chronically increased BP is closely linked with aberrant immune
responses (reviewed in (62)). Importantly, all mentioned aspects of HT
pathogenesis are, at least partially, controlled by S1P balance.
The effects of S1P on vascular tone are complex and largely de-
pendent on the affected vascular layer. Studies have revealed that S1P
promotes both endothelium-dependent vasorelaxation through the ac-
tivation of S1PR1/3 signaling in ECs, as well as vasoconstriction
mediated via S1PR2/3 receptors expressed in VSMCs [63–65]. Fur-
thermore, vasoactive properties of S1P depend on various factors such
as species, gender, the concentration of S1P, the vascular bed, vessel
diameter and spatial distribution of S1P receptors [66]. Mechan-
istically, receptor-mediated S1P action leads to intracellular Ca2+ rise
and subsequent calmodulin-dependent myosin light chain kinase
(MLCK) activation in VSMCs, or calmodulin-dependent eNOS activation
and NO production in ECs. S1P also acts through a Ca2+-independent
mechanism, i.e the Rho associated coiled-coil containing protein kinase
1 (Rock1) activation which promotes myosin light chain phosphatase
(MLCP) phosphorylation resulting in VSMCs contraction. Futhermore,
S1P acts through phosphatidylinositol 3-kinases (PI3K)-Akt/protein
kinase B (PKB) and their subsequent eNOS phosphorylation in ECs
which trigger vasorelaxation [66,67]. Interestingly, while HDL exerts
known vasodilatory effect on vessels, Perségol et al. demonstrated that
this effect is significantly enhanced by S1P [68]. This suggests a pivotal
role of S1P in HDL-mediated vasodilation.
AngII promotes a biphasic Ca2+ increase in VSMCs. The first peak
results from inositol 1,4,5-tris-triphosphate (IP3) signaling and ER store
depletion, which consequently triggers a sustained influx of extra-
cellular Ca2+ through store-operated calcium channels (SOCs) in a
process called store-operated calcium entry (SOCE). Stromal interacting
molecule-1 (Stim1) is a key mediator of SOCE, which after sensing low
Ca2+ concentrations in the ER, binds and activates plasma membrane
proteins, Orai that constitute the pore-forming unit of SOCs. This allows
channels opening and extracellular calcium influx. Interestingly, SOCE
appears to be an independent mediator of experimental hypertension
(for details see [69–71]). Importantly, studies shows that the process of
SOCE-mediated extracellular calcium mobilization is regulated by S1P
Fig. 1. Sphingosine-1-phosphate (S1P) and the embryonic development.
S1pr - sphingosine-1-phosphate receptor, Sphk – sphingosine kinase, RBC – red blood cell, KO – knockout mice. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article).
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in a receptor-independent manner by the direct binding of intracellular
S1P to the EF/SAM1 domain of the Stim1 protein [58,72]. Additionally,
intracellular S1P may play a role in ECs by promoting the recruitment
of heat shock protein 90 (hsp90) to eNOS, leading to increased NO
production as previously shown in the endothelium of the rat aorta
[73].
Studies investigating vasoactive properties of S1P often demonstrate
seemingly opposite conclusions concerning its effect on BP levels and
HT development. Early studies demonstrated that intravenous admin-
istration of S1P produces a rapid and transient decrease in the mean
arterial pressure (MAP) in anesthetized rats. Interestingly, it was re-
cently demonstrated that activation of the S1P/Sphk1/S1pr1 axis is
necessary for the rapid BP lowering effect of the endogenous cannabi-
noid, anandamide in anesthetized mice [74]. However, continuous
administration of S1P results in hypertension in conscious rats, as well
as in wild-type mice, but not in S1pr3 knockout mice [75]. Importantly,
Cantalupo and colleagues showed that mice lacking transcription factor
Nogo-B, which is an inhibitor of the rate limiting step of de novo
sphingolipid synthesis, are hypotensive and do not develop HT in re-
sponse to AngII infusion. Additionally, intraperitoneal injection of
S1pr1 agonist, SEW2871, also reduced systolic BP of AngII-infused
hypertensive mice [76]. In line with the above, S1pr1 receptor activa-
tion was identified as a crucial factor of flow-mediated vasodilation and
EC-specific S1pr1 knockout mice were characterized by the increased
baseline BP, as well as an elevated BP following AngII infusion [77].
Lately, Swendeman et al. demonstrated that administration of S1P
chaperone (ApoM-Fc protein), that is a carrier for plasma S1P, reduces
the BP level in AngII-infused hypertensive mice and is accompanied by
an increase in plasma nitrite production. This effect is completely
abolished after treatment with S1pr1 inhibitor [78]. On the other hand,
Lorenz and colleagues showed that mice lacking S1pr2 exhibit impaired
vasoconstriction responses and thus are characterized by reduced per-
ipheral vascular resistance [79]. Crucially, it has been shown that
experimental hypertension results in an elevated S1P plasma level
[59,80] and that mice with a global deletion of Sphk1 develop less se-
vere AngII-dependent HT [58,59,80]. Recently, our group has found
that pharmacological inhibition of Sphk1 with the selective inhibitor-
PF543, improves endothelial function by altering the eNOS phosphor-
ylation status in mesenteric arteries of hypertensive mice. However this
effect was independent of BP [81]. Thus, in order to dissect specific,
vascular effects of sphingosine kinases, it would be of great value to
study EC- and VSMC-specific Sphk1 and/or Sphk2 knockout mice and to
further characterize autocrine mechanisms of S1P action. Moreover, it
can be postulated that specific overexpression of S1pr1 in the en-
dothelium might be potentially beneficial for vascular function and
should be examined in animal models of HT.
Recent experimental studies in aged mice suggest that there exist
significant sex-dependent differences in S1P-mediated vascular changes
[82]. While currently most studies investigate S1P effects in male ani-
mals exclusively, there is a need to involve both male and female ani-
mals in future in vivo studies as sex may significantly affect S1P action.
Besides the effects on vascular tone, S1P directly affects kidney
functioning. Graham et al. identified S1pr1 as one of the candidates for
salt-sensitive hypertension of stoke-prone spontaneously hypertensive
rats (SHRSP) [83]. Importantly, salt-loaded SHRSP were characterized
by a decreased level of kidney S1pr1 as compared to levels in WKY rats.
Other studies have shown that S1P affects urinary Na+ excretion and
alters BP level through S1pr1 activation [84,85]. Moreover, S1P pro-
tected renal tissue against ischemia/reperfusion injury [86]. Thus, a
reduced level of S1pr1 in the kidneys of SHRSP rats may explain the
decreased renoprotective effects of S1P in these animals [83].
Emerging evidence from the past decades established a significant
contribution of the immune system during the development of HT.
Chronic inflammation caused by an accumulation of immune cells in
organs regulating BP (such as perivascular fat tissue, kidneys, heart and
brain), disrupts physiological homeostasis and may lead to HT [87–91].
Fig. 2. S1P signaling in the vasculature.
S1PR - sphingosine-1-phosphate receptor, P-VEGFR2- phosphorylated vascular endothelial growth factor receptor 2, eNOS- endothelial nitric oxide synthase, hsp90-
heat shock protein 90, SOCE- store operated calcium entry.
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Crucially, S1P plays a significant role in the regulation of adaptive
immune responses as it promotes naïve T cell survival and is crucial for
lymphocyte trafficking [92–94]. S1PR1 expression on T cells and the
S1P gradient, which is low in lymphoid organs in comparison to their
exit sites, are required as a spatial cue for lymphocyte egress from the
thymus and from secondary lymphatic organs before entry into the
blood and lymphatic circulation [94–96]. Studies have established that
the main contributor to the plasma S1P pool required for lymphocyte
trafficking are erythrocytes, while lymph S1P is derived primarily from
lymphatic ECs [9,94,96,97]. Sphks-deficient mice are characterized by
an upregulated S1pr1 expression in lymphocytes, a lack of S1P and
reduced amount of T and B cells in plasma and lymph [9]. Furthermore,
mice with the genetic deletion of S1pr1 in hematopoietic cells display
disturbed lymphocyte egress from the thymus and secondary lymphoid
organs [98,99].
Importantly, it has been demonstrated that Sphk2 knockout mice
(Sphk2−/−) are characterized by T cell accumulation in the mesenteric
lymph nodes and have a blunted BP level in the hypertensive state as
compared to levels in the WT animals, thus Sphk2 has been proposed as
a key sphingosine kinase isoform responsible for T cell egress in HT
[80]. Recently, Don-Doncow et al. observed that progression of HT is
accompanied by S1P and T cells accumulation in the brain which causes
neuroinflammation and leads to cognitive impairment. Moreover, ge-
netic Sphk1 knockout prevented such changes in the brain of hy-
pertensive mice [100].
Among modulators of S1PRs function, FTY720 (also known as
Fingolimod) was the first agent with proven immunosuppressive
properties [101,102]. Currently, it is a clinically approved drug used in
the treatment of multiple sclerosis [103]. FTY720, which is a structural
homolog of sphingosine, becomes phosphorylated by Sphk2 and, in this
active form, acts as an agonist for S1PR1 (initially) and for S1PR3-5
receptors. However, the ability of FTY720 to cause peripheral lym-
phopenia results from functional antagonisms towards S1PR1, which
promotes receptor internalization and its subsequent degradation in T
cells [101,102]. Several studies testing FTY720 action in various animal
HT models were conducted, however, they demonstrated seemingly
contradictory results. It is important to stress that besides the im-
munosuppressive properties of FTY720, which may provide protection
against HT development, S1pr1 downregulation in ECs is associated
with increased endothelial dysfunction (discussed earlier) and may re-
sult in exacerbation of HT. Similar to endogenous S1P, FTY720 pri-
marily triggers a transient BP decrease acting through the S1PR1 re-
ceptor on ECs, and its subsequent downstream activation of eNOS
signaling. However, chronic stimulation with the drug results in S1PR1
internalization, which promotes the binding of plasma S1P to S1PR2
and S1PR3 resulting in vascular contraction [104].
Meissner et al. demonstrated that chronic FTY720 administration,
prior HT development, triggers peripheral lymphopenia and thus pre-
vents AngII-induced development of HT. Importantly, authors demon-
strated that FTY720 was not effective when administered in the animals
with established HT [80]. On the other hand, other studies do not
support protective effects of FTY720 in HT in vivo. Fryer et al. de-
monstrated that chronic administration of the drug increases BP in a
dose-dependent manner in normotensive rats [105]. Moreover, Spijkers
and colleagues confirmed a similar action of the drug in hypertensive
rats 24 h after single-dose treatment, although in normotensive animals
BP was significantly reduced [106]. Finally, Cantalupo et al. found that
chronic FTY720 administration impaired S1P-, Ach-, flow-mediated and
endothelium-independent dilation of mesenteric arteries, as well as
increased BP of hypertensive mice [77]. Differences regarding results of
the above studies may be explained by the differing treatment regimens
e.g. difference in a dose and frequency of drug administration. There-
fore, the exact effects of in vivo FTY720 administration on BP should be
further investigated in various animal models of HT. It would be of
interest to perform an in-depth analysis of molecular mechanisms of the
regulation of S1PR1 internalization and degradation in order to find
other ways to genetically or pharmacologically modulate receptor ac-
tivity in different cell types, and particularly in T cells and ECs.
Results supporting the deleterious FTY720 effect on BP in vivo are in
line with phase III clinical studies which test drug safety and efficacy in
multiple sclerosis treatment. It was demonstrated that the incidence of
HT among patients receiving FTY720 was significantly higher com-
pared to incidences in those receiving placebo [107]. A recent, large
genome-wide association study (GWAS) confirmed that genes involved
in S1P signaling affect the level of blood immune cells in humans [108].
Using UK Biobank data, Astle and colleagues demonstrated that single
nucleotide polymorphisms (SNPs) in SPHK1 and S1PR1 loci associate
with the absolute count of blood lymphoid cells, while SNPs in SPHK2
and S1PR4 loci correlate with the absolute count of, among others cell
types, total myeloid cells. Interestingly, among the various major white
blood cell populations, only the lymphoid cell count level was asso-
ciated with coronary heart disease, yet not with chronic kidney disease,
using Mendelian Randomization (MR) analysis [108,109]. In line with
this, a recent study by Siedlinski et al. found evidence in support of a
potential causal, positive effect of blood lymphocyte count on blood
pressure indices using observational data and MR approach [110]. Of
note, GWAS also supports an association of SNP in the 3′UTR of S1PR2
with BP-related indices, yet the association comes from a locus rich in
various genes, including ICAM1 and DNMT1 [111,112]. Thus, it is of
future interest to test whether genetic determinants of blood lymphoid
cell level and SPHK1, S1PR1 and S1PR2 associate with tissue infiltra-
tion of inflammatory cells and/or related clinical outcomes.
3.2. S1P, endothelial barrier and angiogenesis
Endothelial barrier is crucial for the selective transport of fluids and
solutes between the blood and the surrounding tissue [113]. In-
tracellular contractile forces, provided by actin-myosin crosslinking, as
well as, cell-cell and cell-matrix interaction which generates tethering
forces, are of great importance in the maintenance of vascular wall
integrity [114,115]. Additionally, the presence of endothelial glyco-
calyx (EG), which consists of proteoglycans, hyaluronan, glycoproteins
and plasma proteins, and coats the luminal surface of vessels is another
important factor in the blood-to-tissue barrier [116]. A sustained in-
crease in endothelial permeability leads to vascular leakage and carries
profound consequences such as hemorrhage, edema or inflammation
[17]. Reduced endothelial barrier is a hallmark of acute inflammatory
diseases such as sepsis and acute lung injury (ALI) [117], promotes
cancer cells invasion and metastasis [118], and is an important con-
tributor to atherosclerotic development [24].
It has been established that S1P possesses potent barrier-protective
properties [17,119–121]. Garcia and colleagues investigated the effects
of S1P in microvascular ECs in vitro and demonstrated a dose-dependent
increment in transmonolayer electrical resistance [120]. This effect was
linked to S1PR1 and S1PR3 signaling, and the downstream activation of
small GTPases part of the Rho family which affect cytoskeletal orga-
nization [120]. Other studies further confirmed that barrier-enhancing
properties of S1P are associated with a positive regulation of adherens
junction and tight junction assembly and indicate S1pr1/Rac as a key
mediator of S1P action [17]. An in vivo study performed by Camerer
et al. demonstrated that mice lacking S1P in the plasma, and subjected
to anaphylaxis and platelet-activating factor (PAF) or histamine ad-
ministration, exhibit enhanced vascular leakage resulting in high
mortality. Interestingly, the administration of erythrocytes, i.e. the
main source of S1P in the plasma, restored the endothelial integrity in
S1P-deficient mice [122]. Moreover, oral administration of FTY720
inhibited vascular endothelial growth factor (VEGF)-induced vascular
leakage in mice [123]. Conversely, S1pr2, S1pr3 and downstream Rho
activation was associated with increased vascular permeability both in
vitro and in vivo [124–127]. Interestingly, Sun et al. showed that pa-
tients with sepsis or ALI have increased S1PR3 protein levels in the
plasma as compared to levels in the control group, thus S1PR3 was
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proposed as a novel biomarker for ALI severity [128]. Recently, Re-
inhard and colleagues demonstrated that S1PR1/Gαi/Rac1 and S1PR1/
Gαi/Cdc42 signaling promotes EC spreading and vascular barrier in-
tegrity, while S1PR2/Gα12/13/RhoA signaling increases endothelial
permeability by inducing cell contraction. It was additionally revealed
that early activation of RhoA inhibits signaling driven by Rac1 but not
Cdc42, thus the rapid increase in endothelial integrity triggered by S1P
is provided by the activation of Cdc42 [129]. Crucially, the effect of S1P
on vascular permeability strongly depends on its concentration. Studies
demonstrated that in physiological conditions S1P acts as a barrier-
protective agent, while in higher concentrations (e.g. > 5 μM) S1P
causes endothelial barrier disruption [17,130,131].
Interestingly, the mechanism of action of S1P closely resembles that
of activated protein C (APC), i.e. another known barrier enhancing
agent [132]. Indeed, studies demonstrated that APC binds to en-
dothelial protein C receptor (EPCR) and mediates PI3K/Akt-dependent
phosphorylation of S1pr1 at threonine 236. Moreover, S1pr1 silencing
in ECs treated with the barrier disrupting agent- thrombin, reduced
APC/Rac1-mediated barrier protection. Importantly, recombinant
human APC was tested in clinical trails to treat severe sepsis, however,
it eventually failed as it showed the same results as placebo [133].
Several reports have linked S1P with the remodeling of glycocalyx,
which covers the vascular endothelium. Early studies demonstrated
that plasma albumin stabilizes EG structure and its depletion results in
glycocalyx shedding from endothelial surface and disruption of barrier
integrity [134,135]. Thus, Zeng and colleagues decided to test whether
S1P may be responsible for the stabilizing function of albumin. Indeed,
in vitro studies showed that S1P acting via S1pr1 suppresses the activity
of metalloproteinases (MMPs) that mediate EG shedding, and thus may
restore the endothelial barrier after albumin depletion [134]. Further
investigation revealed that S1P not only stabilizes EG, but is responsible
for its synthesis and this process is mediated via activation of PI3K
signaling [136]. The protective effects of S1P on EG were subsequently
confirmed in ex vivo treated microvessels isolated from rats [137].
Recently, the same group showed that S1P inhibits tumor cell adhesion
to the microvessel walls by regulating EG and vascular permeability
[138]. It was also demonstrated that S1P restores inter-endothelial
transport, mediated via gap junctions by preventing EG shedding and
thus, enables communication between ECs in vitro [139]. Furthermore,
S1P administered during resuscitation following hemorrhagic shock
improved endothelial barrier integrity and protected against micro-
vascular leakage in rats [140]. Indeed, S1P is considered as the main
contributor to the protective effect of therapeutic plasma administra-
tion in patients after trauma-hemorrhagic shock [141].
Altered vascular permeability is linked to aberrant postnatal an-
giogenesis [113,115]. Angiogenesis is the process of new blood vessel
formation from pre-existing ones. Physiologically, it occurs mainly
during embryonic development and in adults is restricted to processes
such as wound healing, skeletal growth, pregnancy and menstrual
cycle. Pathological (excessive) angiogenesis underlies the pathogenesis
of cancer and other disorders [142]. Conversely, insufficient blood
vessel formation prevents tissue regeneration following myocardial
infarction or stroke [143,144]. The master regulators of angiogenesis,
hypoxia-inducible factor (HIF) and vascular endothelial growth factor
(VEGF) are activated in tissue deprived of oxygen, and mediate neo-
vascularization via increasing vascular permeability, induction of EC
proliferation, migration and tube formation [145]. Subsequent re-
cruitment of mural cells and deposition of basement membrane pro-
vides vessel stabilization and maturation [146].
Studies revealed that S1P counteracts VEGF function and prevents
excessive vessel sprouting by sealing the endothelial barrier. S1P pre-
vents vascular endothelial (VE)-cadherin internalization and thus sta-
bilizes endothelial cell adherens junctions via S1PR1 [147]. Ad-
ditionally, S1P/S1PR1 signaling activation downregulates VEGF-
induced phosphorylation of VEGF receptor 2 (VEGFR2), ERK1/2 and
Akt, while S1PR1 ablation is associated, conversely, with
hypersprouting of developing vessels [147]. However, the exact me-
chanism of angiogenic S1P action still remains to be elucidated, since it
is not known if it directly inhibits VEGFR-2 signaling or whether it is a
secondary effect of increased VE-cadherin action, which is able to re-
cruit phosphatases to the VEGFR-2 signaling complex. Interestingly,
although it was previously shown that S1P/S1pr1 signaling stimulates
mural cell recruitment thus stabilizing developing vessels [52], Gaengel
et al., as well as Jung et al. argue with this, as they did not observe a
significant difference in pericyte coverage of vessels in mice lacking
S1pr1 as compared to control [147,148]. Jung and colleagues ad-
ditionally revealed that blood flow is able to evoke activation of S1pr1
signaling in ECs in a ligand-independent manner both in vitro and in vivo
[148]. In general, it is proposed that VEGF is responsible for vascular
network formation, while S1P/S1PR1 signaling in ECs provides vessel
stabilization via adherens junction formation [149]. Interestingly, re-
cent studies have indicated S1P/S1PR3-mediated VEGFR2 activation as
the mechanism of pro-angiogenic effects of HDL [150].
Lately, it has been shown that Sphk1 knockout mice exhibit delayed
skin wound healing as compared to wild-type animals due to impaired
angiogenesis and recruitment of inflammatory cells. In line with this,
Sphk1 overexpression was associated with improved wound closure and
less scaring. Interestingly, it was shown that wounds of S1pr2 knockout
mice healed significantly faster than those of wild-type mice, where
S1pr2 expression increased at the end of wound healing in order to
inhibit S1pr1-mediated wound closure and to prepare the wound for the
remodeling processes [151].
Excessive angiogenesis is a feature of certain types of vascular eye
diseases. It has been shown that S1pr2 knockout mice exhibit reduced
pathological neovascularization of the retina in a model of retinopathy
of prematurity [152]. Furthermore, antibody that neutralized S1P in-
hibited angiogenesis and sub-retinal fibrosis and was suggested as po-
tential future treatment for exudative age-related macular degeneration
[153]. In addition, pathological neovascularization is necessary for
tumor growth and provides a route for cancer cell spread. Advances and
current knowledge of the role of S1P in tumor angiogenesis were re-
cently reviewed by Hisano et al. [149]. It is postulated that S1P sig-
naling has a proangiogenic role during tumor formation and may serve
as a promising target in future cancer therapies. S1P-related drugs are
currently being tested in clinical trials [154]. Understanding S1P action
in angiogenic recovery after myocardial infarction or stroke is still
poorly understood, thus it represents an interesting avenue for future
studies.
3.3. S1P and atherosclerosis
Vascular dysfunction due to impaired endothelial vasodilation, in-
creased vascular permeability, oxidative stress and inflammation pre-
cedes development and drives the progression of atherosclerosis, which
is characterized by hardening and subsequent narrowing of the arteries
and the formation of cholesterol-rich plaques in the vessel wall
[155,156]. Atherosclerosis is linked to dyslipidemia including increased
plasma level of triglycerides and apoB-containing lipoproteins such as
LDL, intermediate-density lipoprotein (IDL) and VLDL, known as
atherogenic, and decreased anti-atherogenic HDL [157,158]. Except for
the known role of HDL in reverse cholesterol transport, which helps
maintain cholesterol balance in the body, HDL is considered to be an
anti-inflammatory, anti-oxidative, anti-thrombotic, pro-angiogenic and
vasorelaxant factor [159].
Association between S1P and atherosclerosis still remains to be fully
understood. This is due to the fact that, as emphasized earlier, S1P
action depends on the plasma S1P carrier and S1P receptor downstream
signaling. S1P/S1pr1/S1pr3 axis activation enhances endothelial bar-
rier and endothelial cell-cell junctions [147] and promotes vasor-
elaxation via eNOS activation [67] and thus is considered to be anti-
atherosclerotic. Interestingly, HDL vasodilatory properties are inhibited
in S1pr3 knockout mice, which supports the notion that S1P plays a
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central role in HDL action [65]. Furthermore, HDL-associated S1P
prevented apoptosis of ECs [160,161]. It was also shown that the HDL/
apoM carrier strengthened agonist properties of S1P towards anti-
atherosclerotic S1pr1 signaling, while albumin-carried -S1P activates
S1pr1 to a limited degree [24]. Another important feature of athero-
sclerosis is inflammation initiated by monocytes, which recognize ad-
hesion molecules presented on the surface of the endothelium and are
recruited to the subendothelial space [162,163]. In most studies S1P is
considered to enhance the expression of adhesion molecules [164].
However, other studies have reported that S1P suppresses the process of
monocyte adhesion [165,166] and this effect could be mediated by
integrin rearrangement in ECs [165]. Additionally, it was recently
shown that S1P, as well as HDL-bound S1P acting via S1PR2/3 promote
signal transducer and activator of transcription 3 (Stat3) and survivin
expression and thus reduces macrophage apoptosis. Such effects may be
beneficial, as sustained death of macrophages in late atherosclerotic
lesions is associated with accelerated disease progression [167]. Ad-
ditionally, Tamama et al. showed that HDL-bound S1P inhibits VSMCs
migration and thus affects plaque stability, while its effects on VSMCs
proliferation remains controversial [168]. Recently, Keul and collea-
gues found that HDL-associated S1P acting via S1PR2 exerts anti-in-
flammatory properties in VSMCs due to inhibition of tumor necrosis
factor-α (TNF-α) signaling [169]. Similarly, apoM-bound S1P inhibited
inflammation in ECs via S1PR2-mediated activation of PI3K/Akt sig-
naling [170]. Pro-angiogenic S1P properties might be related to S1P-
mediated chemotaxis of lymphocytes, NK cells, monocytes and mac-
rophages and to its pro-thrombotic properties [24,171]. However, mice
deficient in the LDL receptor, fed a high cholesterol diet and adminis-
tered a sphingosine kinase inhibitor, SKI-II, developed more severe
atherosclerosis than these receiving placebo [172]. In line with this,
Feuerborn et al. showed that elevation of endogenous S1P alleviates
atherosclerosis in LDL receptor-deficient mice [15]. In summary, on the
basis of studies utilizing animal models with specific, genetic S1pr de-
letion or given a S1pr agonist, it might be concluded that the effects of
S1P are mostly anti-atherosclerotic when mediated via S1pr1 and S1pr3
and possibly pro-atherosclerotic when mediated via S1pr2 [24,173].
Crucially, patients with coronary artery disease (CAD) are char-
acterized by reduced S1P content in HDL as compared to healthy in-
dividuals [174] and it was reported that S1P-loading improves pro-
tective HDL signaling in the endothelium [175]. Moreover, therapeutic
S1P-loading of CAD-HDL restored HDL function in VSMCs [169].
In conclusion, S1P is an important mediator of various vascular
processes and the complexity of S1P actions in regulating vascular tone,
endothelial permeability, angiogenesis, hypertension and athero-
sclerosis certainly requires further investigation. However, the overall
conclusion emerges that signaling through S1P type 1 receptor seems to
be particularly beneficial in the vasculature as it improves endothelial
function, strengthens endothelial barrier integrity, inhibits aberrant
angiogenesis and possesses anti-atherosclerotic properties.
4. S1P and postnatal cardiac homeostasis
Numerous studies have established both physiological and patho-
physiological roles of S1P in both acute cardiac responses (cardiac in-
otropy and chronotropy), as well as in chronic processes (such as
apoptosis and hypertrophy) occurring in the cardiac tissue (Fig. 3).
4.1. S1P and cardiac contractility
The heart is an autonomous organ that does not require external
stimuli to generate or conduct an electrical impulse causing atria and
ventricles to contract. However, cardiac innervation by sympathetic
adrenergic nerves and parasympathetic cholinergic nerves affects the
excitability and conductivity of cardiac muscle, as well as the frequency
and the force of contraction, by changes in intracellular calcium con-
centration [176]. Norepinephrine, a neurotransmitter released from the
sympathetic nerve endings, binds to β-adrenergic receptors on cardiac
cells and promotes an increase in heart rate (a positive chronotropic
effect) and in cardiac contractility (a positive inotropic effect). Para-
sympathetic signaling, mediated via acetylcholine and muscarinic re-
ceptors, results in opposite cardiac effects i.e. lower heart rate and re-
duced cardiac contractility [177].
It has been established that S1P acting through GPCRs can modulate
Ca2+ handling by activating specific G-protein signaling. Indeed,
Landeen et al., as well as Means et al. demonstrated that S1P affects
cardiac muscle contraction. Studies show that in adult mouse ven-
tricular myocytes, S1P evokes negative inotropic effects associated with
decreased myocyte shortening [49,178]. Authors suggested that acti-
vation of S1pr1 (with a minor role of S1pr3), and thus Gαi protein
signaling, antagonizes β-adrenergic responses by inhibiting adenylyl
cyclase/cAMP-associated decrease in L-type calcium channel current
(ICaL). Additionally, Gβγ subunit release results in an increase in out-
ward K+ current (IKAch) and shortens the duration of the action po-
tential, which in turn decreases Ca2+ influx and further explains the
negative inotropic effect of S1P. The importance of S1pr1 signaling in
mediating negative inotropy was further confirmed with the use of
cardiomyocyte-specific S1pr1 knockout mice [179].
S1P also acts as a negative chronotropic agent affecting heart rate.
Early studies have demonstrated that S1pr3 specifically mediates
transient bradycardia in vivo [180]. Administration of non-specific S1P
receptor agonists induced bradycardia in wild type mice, however, such
an effect was not observed in S1pr3 knockout mice. In line with this,
S1pr1 agonist treatment did not result in alteration of the heart rate.
However, recent studies demonstrated S1pr1 activation as a main de-
terminant of the bradycardic effect in rats and humans [104,105,181].
Importantly, FTY720 is known to produce bradycardia as a side effect
[107,182]. The bradycardic effect of S1P or FTY720 action is dependent
on the G-protein–coupled inwardly rectifying potassium (GIRK) chan-
nels activation, which triggers membrane hyperpolarization and tran-
siently reduces excitability [104,183]. Additionally, as shown by Racca
et al., patients receiving FTY720 have reduced left ventricular systolic
function [184]. Taking this into account, there exists a need to further
improve pharmacological modulators of S1P signaling to avoid dele-
terious cardiac effects [185–187]. A second-generation compound, Si-
ponimod (BAF312), a selective agonist of S1pr1 and S1pr5 receptors
has been recently approved by FDA for the treatment of secondary
progressive multiple sclerosis. However, despite the fact that BAF312
does not activate S1pr3 signaling, it still reduces heart rate, although
this was mitigated by the novel dose titration scheme [185,188]. Cru-
cially, other new generation S1PR-targeting agents (e.g. Ozanimod) are
now being tested in clinical trials and demonstrate potent therapeutic
effects in multiple sclerosis and other autoimmune diseases without
clinically significant heart rate reduction [154,189].
Nonetheless, it should be noted that there exists a significant risk of
adverse cardiac effects associated with systemic administration of S1P
signaling modulators.
4.2. S1P, cardiac hypertrophy and fibrosis
Cardiac hypertrophy is an adaptive mechanism of the heart re-
sponding to environmental changes. Physiological hypertrophy is as-
sociated with normal or increased cardiac function, while pathological
hypertrophy occurs as a consequence of prolonged and abnormal he-
modynamic stress or myocardial infarction, and is accompanied by
systolic and diastolic dysfunction and eventually progresses to heart
failure [190,191]. Morphological thickening of the cardiac walls and
septum results in the loss of chamber area. Thickening is caused by
cardiomyocyte growth, enhanced proliferation and conversion of car-
diac fibroblast to myofibroblasts, as well as interstitial fibrosis due to
excessive production of extracellular matrix (ECM) [192]. Death of
cardiac myocytes is a hallmark of the transition to a decompensatory
stage, which is characterized by thinning of the cardiac wall and
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ventricular dilation [190].
The first in vitro studies provide conflicting information concerning
the effect of S1P on cardiomyocyte hypertrophy. While Sekiguchi et al.
did not observe difference in the cardiac myocyte size after S1P sti-
mulation [193], another study by Robert et al. revealed that S1P sig-
nificantly enhances cardiomyocyte hypertrophy, specifically by acti-
vating S1pr1/Gαi, and downstream ERK1/2, p38, JNK, Akt and Rho
signaling [194]. In vitro studies in cardiac fibroblasts demonstrated that
S1P plays an important role in myofibroblast transformation and reg-
ulates TGF-β-induced production of ECM proteins through S1pr2/Gα12/
13 and Rho kinase signaling activation [195]. In line with this, treat-
ment of mouse cardiac fibroblasts with apelin significantly reduced
TGF-β dependent fibroblast activation and collagen production by the
inhibition of Sphk1 [196]. In vivo studies demonstrated that in basal
conditions, mice treated with S1P were characterized by marked car-
diac myocyte hypertrophy accompanied by an upregulation in the
cardiac hypertrophy marker, atrial natriuretic peptide (ANP), and such
effects were not dependent on BP [197]. On the other hand, Zhang et al.
demonstrated that mice lacking Nogo-A/B systemically or specifically
in ECs, which are characterized by increased local S1P production, are
resistant to the cardiac hypertrophy and dysfunction following trans-
verse aortic constriction (TAC) [198]. Moreover, S1P treatment pre-
vented TAC-induced cardiac hypertrophy via downregulation of histone
deacetylase-2 activity and upregulation of anti-hypertrophic transcrip-
tion factor, Krüppel‑like factor 4 (KLF4) [199]. Crucially, studies per-
formed by Siedlinski et al. revealed a significant reduction of cardiac
mass in Sphk1 knockout mice with no significant changes in cardiac
fibrosis following 2 weeks of AngII infusion as compared to changes in
wild type mice [59]. Furthermore, recently this finding was supported
by a study demonstrating that pharmacological inhibition of Sphk1,
using selective inhibitor PF543, protected AngII-infused hypertensive
mice against development of cardiac hypertrophy without significant
effects on cardiac fibrosis. Mechanisms of PF543 action could be par-
tially mediated by the downregulation of cardiac S1pr1, Rock1, Stat3,
PKC and ERK1/2 signaling [81]. Interestingly, transgenic mice over-
expressing Sphk1 were characterized by increased cardiac interstitial
fibrosis with no effect on cardiomyocyte hypertrophy, which was de-
pendent on S1pr3, i.e. the most abundant type of S1P receptor ex-
pressed by cardiac fibroblasts, RhoA signaling activation and increased
reactive oxygen species (ROS) production, but was independent of
AngII type 1 receptor (AT1) signaling [200]. Furthermore, cardiac fi-
broblast-specific overexpression of S1pr1 in mice resulted in increased
fibrosis, as well as hypertrophy mediated by Stat3 signaling and in-
terleukin 6 (Il-6) production [201]. Importantly, Liu and colleagues
demonstrated that FTY720, is able to reverse an existing pressure
overload-induced cardiac hypertrophy and associated fibrosis and im-
proves cardiac performance by inhibiting NFAT signaling in cardio-
myocytes and by reducing periostin expression in the ECM [202]. Thus,
FTY720 is now considered as a promising new approach in the treat-
ment of heart hypertrophic/fibrotic disease which may ultimately
progress to heart failure.
Human study demonstrated that patients with Fabry disease, which
is linked to abnormal heart morphology, had significantly higher S1P
plasma levels, which positively correlated with left ventricular mass
index. Thus, authors proposed S1P as a marker for cardiac remodeling
in Fabry disease [197]. Since Sphk1 expression and S1P level are ele-
vated in hypertensive [59] or post-myocardial infarction hearts [203],
it would be of great value to investigate changes occurring in the car-
diac sphingolipidome following genetic Sphk1 inhibition and whether
these changes associate with pathological cardiac remodeling.
4.3. S1P, myocardial infarction and heart failure
Myocardial infarction (MI), is characterized by reduced or blocked
Fig. 3. S1P signaling in the heart.
S1PR - sphingosine-1-phosphate receptor, ERK1/2- extracellular signal-regulated kinases 1/2; Stat3- signal transducer and activator of transcription 3; ROS- reactive
oxygen species; cAMP- cyclic adenosine 3′,5′-monophosphate; GIRK- G-protein–coupled inwardly rectifying potassium channels; GSK-3β- glycogen synthase kinase-
3β; eNOS- endothelial nitric oxide synthase.
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coronary blood flow causing oxygen deprivation of the heart muscle
and subsequent death of cardiac cells. The most common cause of MI is
rupture of an atherosclerotic plaque formed during CAD [204]. Over
the past decades studies revealed that S1P (or HDL-bound S1P) pos-
sesses cardioprotective properties and particularly protect cardiomyo-
cytes against apoptosis. In 2001, Karliner et al. demonstrated that
exogenously supplied S1P, as well as Sphk activation by ganglioside
GM-1, prevented hypoxia-induced death of neonatal rat cardiac myo-
cytes [205]. This effect was confirmed in an adult mouse cardiac
myocyte study which also implicated that S1P-mediated apoptosis in-
hibition was dependent on S1pr1 downstream activation of Akt, in-
hibition of glycogen synthase kinase-3β (GSK-3β) and reduction of
cytochrome c release from the mitochondria [48]. Ex vivo experiments
performed by Lecour et al. on isolated perfused rat hearts undergoing
regional ischemia/reperfusion (I/R), revealed for the first time that S1P
has cardioprotective, infarct-sparing effects [206]. The same was shown
in isolated perfused mouse hearts undergoing global I/R. Exogenous
and endogenous S1P protected cardiac muscle from ischemic injury and
the effect of the latter was partially mediated by PKCε [207]. However,
S1pr1 agonist, SEW2781, was not able to protect rat hearts against
global ischemia ex vivo with the same effectiveness as S1P. In vivo
studies utilizing transgenic mice overexpressing Sphk1 showed sig-
nificantly reduced infarct size following ligation of the left anterior
descending coronary artery (LAD) [200]. Accordingly, Sphk1 knockout
mice were more sensitive to I/R injury and the protective effects of
ischemic pre- and postconditioning were impaired in these mice
[208–210]. Lately, Keul et al. in studies using cardiomyocyte-specific
S1pr1 knockout mice showed that S1pr1 is crucial for S1P-mediated
ischemic preconditioning. However, in basal conditions, infarct size
was similar in both, S1pr1 knockout and in wild type mouse groups
[179]. Additionally, a recent study by Kuang el al. has revealed that
endothelium-specific loss of S1pr1 reduces reparative F4/80+Ly6clow
macrophage proliferation and thus exacerbates cardiac remodeling and
aggravates cardiac dysfunction after IR injury in mice [211]. This em-
phasizes the role of coronary microvasculature as an additional target
for cardioprotection, beyond protection of cardiomyocytes [212,213].
Several reports demonstrated that it is S1pr2/S1pr3 rather than
S1pr1 signaling that provides cardioprotection after I/R injury. For
instance, Theilmeier et al. found that HDL-associated S1P protects the
heart against I/R-induced damage through NO signaling and this effect
was not observed in S1pr3 knockout mice [214]. Furthermore, Means
et al. demonstrated that in S1pr2 and S1pr3 double knockout mice in-
farct size was significantly increased following an ischemic insult as
compared to infart size in wild type mice. Mechanistically, the cardi-
oprotective effect of S1P were dependent on Akt/eNOS activation
[40,41,215,216]. Additionally, ex vivo and in vivo studies by Morel et al.
revealed an important role of intracellular signaling via connexin 43 in
a S1pr2/S1pr3 mediated cardioprotection against I/R injury [217].
Another study by Yung and colleagues indicates RhoA signaling as an
alternative mechanism downstream of S1pr3 and Gα13 protein activa-
tion [218].
Importantly, cardioprotective effects of S1P also depend on two
important pathways that converge to provide cardioprotection after
ischemic insult, i.e. the Survivor Activating Factor Enhancement (SAFE)
and the Reperfusion Injury Salvage Kinase (RISK) pathways, which are
activated by protective ischemic pre- and postconditioning, as well as
by pharmacological mimetics of ischemic conditioning [25,219,220].
The first pathway involves TNFα-induced Stat3 activation, and the
latter is mediated via Akt/ERK1/2 signaling. In 2010, Kelly et al.
showed that pretreatment with ethanolamine, which is a metabolite of
S1P, decreases the infarct size in rats and mice subjected to I/R and
activates cardioprotective Stat3 signaling [221]. Subsequent studies
demonstrated that S1P administrated at the onset of reperfusion fol-
lowing ischemia reduces the infarct size in wild type mice, however
genetic and/or pharmacological loss of TNFα or Stat3 prevented such
changes. Furthermore, Akt inhibition also abolished the infarct-sparing
effects of S1P. Upregulated signaling via SAFE and RISK pathways re-
sulted in inactivation of pro-apoptotic and pro-hypertrophic transcrip-
tion factor, forkhead box protein O1 (FOXO-1) [222]. Similarly, other
studies demonstrate Stat3 signaling as a mediator of protective S1P
preconditioning [223]. Based on research by Theilmayer et al., who
demonstrated that pre-treatment with human native HDL and sole S1P
(unbound to HDL) protected mice against reperfusion injury [214],
Brulhart-Meynet et al. proposed an addition of S1P to a synthetic, re-
constituted HDL (rHDL) [224], and administration of such enriched
rHDL at the time of reperfusion (post-ischemic treatment) [225]. Re-
sults revealed that rHDL containing S1P mimics the effect of native HDL
(both ex vivo and in vivo), whereas rHDL in a basic composition is not
sufficient to protect against IR injury. Additionally, rHDL-S1P treatment
was accompanied by the activation of prosurvival ERK1/2, Stat3 and
Akt signaling (225). It is unclear whether S1PR-dependent signaling is
required for RISK and SAFE-mediated cardioprotective S1P/HDL ac-
tions. Currently, S1PR2 receptor is proposed to be a major mediator,
however other receptors may be involved. Additionally, studies indicate
that protective TNF signaling might require intracellular S1P [25].
Valuable results are also provided by studies focusing on degrada-
tion of S1P by lyase (SPL) in the ischemic cardiac tissue. Ex vivo studies
demonstrate that the activity of SPL is induced by ischemia in the heart,
and that mice lacking SPL are characterized by an increased cardiac S1P
level, decreased infarct size and improved functional recovery after I/R
injury. Furthermore, FDA-approved food additive, tetra-
hydroxybutylimidazole (THI), which is known to inhibit SPL, was
tested in an ex vivo mice I/R model and exhibited similar advantageous
properties [226]. In contrast, in vivo studies by Zhang et al. revealed
that THI treatment of mice following LAD ligation procedure, increased
the level of cardiac S1P, however it had an opposing effect on cardiac
function and remodeling [203].
Additionally, Zhang et al. showed that pharmacological inhibition
of Sphk1 improves left ventricular ejection fraction (LVEF) in post-MI
mice [203]. While, following ligation of the LAD artery, Sphk1 activity,
S1P level and S1pr1 expression were increased in the cardiac tissue.
Treatment with a selective Sphk1 inhibitor, PF543, prevented Sphk1/
S1P/S1pr1 pathway activation and upregulation of the cardiac re-
modeling markers such as brain natriuretic peptide (BNP), ANP and β
myosin heavy chain (β-MHC). Accordingly, S1pr1 signaling disruption
by FTY720 treatment in post-MI mice also resulted in significant im-
provement of cardiac function and remodeling, and was associated with
inhibition of post-MI inflammation. Thus, authors proposed using
FTY720 as a post-MI treatment [203]. In line with the above, Santos-
Gallego et al. demonstrated that FTY720 preserves myocardial function
following MI in pigs [227].
Quantification of S1P content after MI in human plasma samples
revealed a significant decrease as compared to controls and low levels
persisted for at least one month after MI. However, it remains un-
resolved whether the observed post-MI S1P decrease in plasma is a
consequence of myocardial infarction itself or/and the result of anti-
platelet therapy that was also given to the patients [228,229]. Im-
portantly, recently Polzin and colleagues demonstrated a negative
correlation of S1P plasma level with LVEF and dyspnea in patients with
ischemic heart disease [230].
Heart failure (HF) is a complex clinical state characterized by in-
sufficient blood supply of the end organs and of peripheral tissues. HF
develops following cardiac hypertrophy and/or myocardial infarction
and is associated with chronic stimulation of β-adrenergic signaling in
cardiac tissue. Recent studies by Cannavo et al. showed for the first time
a direct interaction between β1 adrenergic receptor (β1AR) and S1pr1
[43]. Stimulation of β1AR resulted in the downregulation of the plasma
membrane level of S1pr1, whereas S1pr1 agonists promoted down-
regulation of β1AR. The above study indicated that rats with HF had
lower levels of circulating S1P and Sphk1 and downregulated expres-
sion of S1pr1 in post-MI left ventricular tissue. Thus, Cannavo et al.
proposed S1pr1 gene delivery to prevent left ventricular HF. Indeed, in
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post-MI rats direct intramyocardial injection of adenoviral vectors
containing S1pr1 gene ameliorated cardiac function (by increasing
LVEF) and reversed maladaptive ventricular dilation by promoting a
compensatory hypertrophic response [43]. Unlike in chronic HF,
symptoms of acute HF may occur suddenly [231]. Recent ex vivo studies
in rats demonstrated that S1P administered during recovery after hy-
potensive de novo acute HF, improves the pacemaker ability of the heart
and this may be partially mediated by Stat3 signaling [232].
In summary, the mechanism of S1P action in cardiac physiology and
pathology is highly sophisticated since S1P affects many different
processes that control overall heart function. Although in the case of
acute cardiac responses S1P action seems to be only associated with
negative inotropy and negative chronotropy, the effects of S1P in
chronic cardiac processes are far more complex. In general, S1P is
considered to have cardioprotective properties as most studies revealed
that it improves cardiomyocyte viability, protects against ischemic in-
jury and might be beneficial in HF. On the other hand, S1P was shown
to possess pro-hypertrophic properties as well. Thus, it should be fur-
ther investigated in long term studies whether S1P signaling in the
heart, exposed to stress conditions, prevents or rather drives the pro-
gression to HF. Future studies should therefore carefully define the
characteristics of the condition/disease model and should determine
the specific stage and severity of HF progression, where S1P signaling
modulation is tested.
5. Summary
In conclusion, S1P affects the function of the cardiovascular system
on multiple levels. Given the fact that S1P acts as an intracellular sig-
naling molecule or as a ligand for various receptors differentially ex-
pressed on the cell and tissue level, and affects most processes that are
crucial for a functioning cardiovascular system, it is challenging to
dissect a specific molecular mechanism that translates into observed
phenotypic change. Thus, in order to accomplish this, future research
should use more targeted approaches to avoid introducing systemic
changes in S1P metabolism and signaling. Currently, modern pharma-
cological tools such as biased agonist of S1PRs, S1P neutralizing agents,
transporter modulators, chaperone-mimicking agents and others, are
being developed [154]. Therefore we might be able to effectively use
the potential of S1P in the treatment of cardiovascular diseases in the
near future.
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